Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Positive data reported from phase II study of IONIS-GCGRRx

Jan. 5, 2017

Caelum Biosciences formed to develop CAEL-101

Jan. 5, 2017

CymaBay Therapeutics signs license agreement with Kowa for arhalofenate in U.S.

Jan. 4, 2017

Agile reports phase III topline results for Twirla hormonal contraceptive patch

Jan. 4, 2017

Soliqua available in U.S.

Jan. 4, 2017

Saniona reports topline data from phase IIa study of Tesomet in type 2 diabetes

Jan. 3, 2017

X4 initiates phase II/III trial of X4P-001 in patients with WHIM syndrome

Jan. 3, 2017

Lilly describes MetAP2 inhibitors

Jan. 3, 2017

Fuji Yakuhin opens phase III study of FYU-981 in patients with hyperuricemia with or without gout

Jan. 2, 2017

OPKO's phase III study of hGH-CTP does not meet primary endpoint

Jan. 2, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 9, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026